Income Taxes (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Nov. 28, 2018	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets		$ 6,800
Income tax examination description		The federal portion of the deferred tax assets and liabilities were re-rated from 34% to 21% percent pursuant to the 2017 Tax Act.
Income tax rate		21.00%	34.00%
Net operating loss carryforwards		$ 15,204	$ 11,414
Research and development credit carryforwards		2,444	2,141
Change in valuation allowance		$ 4,800	1,100
Income tax other description		The amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation.
Accrued interest and penalties
BioTime, Inc. [Member]
Sale of common shares			266,442
Market transactions taxable loss			$ 301
AgeX Therapeutics, Inc [Member]
Sale of common shares	35,326
Gain on taxable income	$ 100
Federal [Member]
Net operating loss carryforwards		$ 59,000
Net operating loss expiration period description		between 2030 and 2037
State [Member]
Net operating loss carryforwards		$ 28,000
Net operating loss expiration period description		between 2029 and 2037
Federal and State [Member]
Net operating loss carryforwards		$ 1,300
Net operating loss expiration period description		between 2020 and 2023
Research and development credit carryforwards		$ 1,200
Credit carryforward expiration term		between 2030 and 2038